mAb have been developed against a great variety of targets, such as the HER2 pathway, ICI, human epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and others, and some of these are approved to be used as a therapy for BC while others continue under study [43]. Here, ERBB2 is linked to breast cancer.